Still lifetime of Wegovy an injectable prescription weight reduction medicine that has helped individuals with obesity. It must be used with a weight reduction plan and physical activity.Â
Michael Siluk | UCG | Getty Images
Novo Nordisk’s Wegovy cut the danger of great cardiovascular complications in individuals with obesity and heart disease in a closely watched trial, demonstrating a very large effect on heart attacks, a promising recent frontier for the drug.
The roughly 17,500-person Select study tested Wegovy in individuals with obesity and heart disease but who didn’t have diabetes. Weekly injections of Wegovy slashed the general risk of heart attack, stroke and death from cardiovascular causes by 20%, in accordance with detailed results from the trial presented Saturday on the American Heart Association Scientific Sessions and concurrently published within the Recent England Journal of Medicine. Novo Nordisk disclosed topline data from the study in August.Â
The findings could expand insurance coverage of Wegovy, a serious barrier to date for the drug and similar GLP-1 agonists, and spur broader use of the anti-obesity drug.
“That is the primary time that medication approved for chronic obesity management may be considered life saving,” said Dr. Robert Kushner, a professor of medication in endocrinology on the Northwestern University Feinberg School of Medicine who was involved with the study.
The brand new data could also help the Danish pharmaceutical company maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was approved within the U.S. earlier this week. Zepbound has been shown to assist people lose more weight, but it surely hasn’t yet demonstrated an effect on cardiovascular outcomes.Â
“For those who take a look at where the insurance firms are going to be obliged to go, they’ll be obliged to go together with the drug that reduces cardiovascular events,” said Dr. Howard Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart who was involved with the study.
Trial results
Wegovy reduced the danger of non-fatal heart attack by 28% within the five-year trial. It produced a smaller 7% reduction within the occurrence of non-fatal stroke, though few strokes were seen within the trial overall.
What’s more, Wegovy began to point out a discount in overall cardiovascular events inside months of participants starting the drug, with the difference between the drug and placebo widening because the study continued. Researchers observed that effect even before people lost significant weight, a “fascinating” finding that means each weight reduction and the drug itself might be playing a task in heart health, said Dr. Ania Jastreboff, director of the Yale Obesity Research Center.
“I feel it’s all additive, and I do not think we will parse out one from the opposite,” Jastreboff, who was not involved within the study, said at a press briefing.
About two-thirds of participants had blood sugar levels that put them within the range of prediabetes. Wegovy decreased progression to diabetes by 73%, suggesting the drug might be used as an early treatment. Novo’s Ozempic, which uses the identical lively ingredient as Wegovy, is approved for diabetes.Â
The study enrolled each patients whose body-mass index met the edge for obese or obesity, though a lot of the patients were considered obese.
Unwanted side effects and limitations
Almost 17% of individuals receiving Wegovy within the trial stopped taking the drug, mainly due to gastrointestinal issues like vomiting and diarrhea, double the speed of people that discontinued the placebo. But more people within the control group experienced serious antagonistic events akin to cardiac disorders and medical procedures.Â
The discontinuations may reflect less familiarity with Wegovy amongst doctors involved within the study, said Kushner, who makes a speciality of caring for patients who’re obese or have obesity. Adjusting the dosage or tweaking weight loss program can assist people navigate unpleasant unwanted side effects.
Participants also lost less weight on this study than previous ones examining Wegovy, though this study didn’t incorporate lifestyle changes and it enrolled individuals with different characteristics.Â
One limitation of the study was its lack of diversity. Nearly three-quarters of the participants were male, and much more were white. Nearly 4% of participants were Black.
Regardless, doctors expect the outcomes to extend the number of people that take Wegovy.Â
Seeing a diabetes drug producing positive cardiovascular and metabolic effects “opens a recent door to treat obese patients with heart problems,” said Dr. George Dangas, director of cardiovascular innovation for Mount Sinai Hospital. However it could take time and energy to include it into clinical practice.
“Those are good problems to have,” Dangas said. “We have now something good for the patient, that is great.”Â
— CNBC’s Patrick Manning contributed to this report.
CORRECTION: This text has been updated to correct the title of Dr. George Dangas, director of cardiovascular innovation for Mount Sinai Hospital.
